Canopus BioPharma Inc. announces positive results from an In-Vitro live Ebola Virus study
December 19 2014 - 8:00AM
PR Newswire (US)
LOS ANGELES, Dec. 19, 2014 /PRNewswire/ -- Canopus BioPharma
Inc. (OTC Pink: CBIA) today announces that it has completed crucial
research in confirming efficacy of a prescription drug: CB008 for
Ebola Virus inhibition.
Laboratories at the Texas Biomedical Research Institute in
San Antonio Texas have
demonstrated complete in-vitro inhibition of the live Ebola
Virus strain Zaire at
concentrations of CB008 that are achievable by oral administration.
CB008 is only one of a family of prescription drugs which has been
demonstrated by Canopus BioPharma to have potential in preventing
Hemorrhagic syndrome and inhibiting Ebola Viral replication.
CB008 is an in-house codename for a well-established
prescription drug first approved by the FDA in the early 1980's for
other medical indications. CB008 is an effective, safe treatment
for Ebola Virus. Canopus BioPharma has signed a confidential
agreement with a major pharmaceutical company who are reviewing the
results and the possibility of expediting an Ebola non-human
primate study. Following this, CB008 can progress to a human Ebola
patient clinical trial in West
Africa.
According to the CDC, the 2014 Ebola Virus epidemic is the
largest in history and is effecting multiple countries. In this
epidemic, 1 in 2 people who get the disease die from it. It can
take up to 21 days for an infected person to develop symptoms from
it. The highly contagious virus is spread through contact with an
infected persons blood or body fluids."What we have shown by the
use of CB008 in tissue culture is how vulnerable these Ebola
viruses are when you interfere with their mechanism of creating
havoc both to epithelial cells and to the immune system," said Dr.
Leo Shanahan-Prendergast from
Canopus BioPharma Inc.
Copyright 2014 PR Newswire
Canopus Biopharma (PK) (USOTC:CBIA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Canopus Biopharma (PK) (USOTC:CBIA)
Historical Stock Chart
From Nov 2023 to Nov 2024
Real-Time news about Canopus Biopharma Inc (PK) (OTCMarkets): 0 recent articles
More Canopus BioPharma Inc. News Articles